Empagliflozin in ESKD - A Feasibility Study
NCT05687058
Recruiting
The aim of this study is to learn about the safety of empagliflozin in dialysis patients as a preparation for a future large clinical trial. Empagliflozin has been approved by the Food and Drug Administration for the treatment of either type 2 diabetes, heart failure, or chronic kidney disease among patients not on dialysis. The use of empagliflozin has not been studied or approved among patients on dialysis for kidney failure because empagliflozin acts on the kidneys. However, recent experiment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Mississippi Medical Center, Jackson, Mississippi +1 locations
Conditions: Kidney Failure, Chronic, Heart Failure
Register for Updates
Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
NCT05864976
Recruiting
This study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Glioblastoma Multiforme
Register for Updates
iMOVE: Virtual Reality PT Versus Traditional PT
NCT05876156
Recruiting
This pragmatic, crossover, randomized controlled study evaluates the efficacy of virtual reality assisted physical therapy (VRPT) for improving the physical activity of hospitalized children as compared to traditional physical therapy. This is a pilot study that will be used to identify patient populations that can benefit the most from VRPT and estimate this effect for future studies. Patients with a significant neurological condition, major developmental disability, active infection of the fa... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
06/19/2025
Locations: Lucile Packard Childrens Hospital Stanford, Palo Alto, California
Conditions: Physical Health
Register for Updates
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367
Recruiting
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +7 locations
Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
Register for Updates
Dual Implant Versus Single Implant Distal End of Femur
NCT06032299
Recruiting
This research study is being conducted to examine the effect of two versus one fixation device for fixation of distal femur fractures.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/19/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Femur Fracture
Register for Updates
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
NCT06108050
Recruiting
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: California Cancer Associates for Research and Excellence, Encinitas, California +9 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection
NCT06139224
Recruiting
Alcohol use disorder (AUD) has been associated with high prevalence of inflammation-associated co-morbidities in people living with HIV even those receiving effective antiretroviral therapy (ART). Our preliminary data support a model in which the combined insult of AUD and HIV on the gut, specifically on the microbiota and intestinal barrier integrity, exacerbates inflammation. Our preliminary data using intestinal organoids also suggest a potential mechanism for AUD-mediated changes in the gut... Read More
Gender:
ALL
Ages:
Between 45 years and 80 years
Trial Updated:
06/19/2025
Locations: Ali Keshavarzian, Chicago, IL 60612, Illinois
Conditions: Alcohol Use Disorder, Human Immunodeficiency Virus
Register for Updates
Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation
NCT06149780
Recruiting
To study the effect of fractionated 1927-nm non ablative thulium laser in reduction of post inflammatory hyperpigmentation (PIH) using a validated and reproducible model for studying PIH. * Determine if there is aa reduction in PIH in patients treated with three (3) monthly sessions of fractionated 1927-nm non ablative thulium laser * Determine if there is efficacy of post-procedure clobetasol propionate 0.05% ointment in the management of PIH * Determine the histological and molecular changes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Henry Ford Medical Center, Detroit, Michigan
Conditions: Healthy
Register for Updates
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596
Recruiting
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +169 locations
Conditions: Metastatic Urothelial Cancer
Register for Updates
Modulating Energy Density in Time-Restricted Eating
NCT06259435
Recruiting
The goal of this randomized controlled trial is to test the effect of time-restricted eating (14-hour fast, 10-hour eating window) of a low-energy dense diet (reduced calories per gram of food) in older adults with obesity and insulin resistance. The study aims to determine if modulating the energy density of the diet reduces: 1. Insulin resistance and 2. Body weight. Researchers will compare the groups: 1. Following time-restricted eating and given a diet reduced in energy density or 2. Foll... Read More
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
06/19/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Insulin Resistance, Body Weight
Register for Updates
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
NCT06319963
Recruiting
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type * either study drug group A: recurrent and/or metastatic cancer * or study drug group B: newly diagnosed with locally advanced can... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Florida Cancer Specialists (from Sarah Canon research Institute), Orlando, Florida +3 locations
Conditions: HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
NCT06320405
Recruiting
This phase I/II trial tests the safety, side effects, and effectiveness of axatilimab in combination with retifanlimab and paclitaxel for the treatment of patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Axatilimab is a monoclonal antibody that may interfere with the ability of tumor cells to gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates